West Pharmaceutical Services (WST) FCF Margin (2009 - 2026)

West Pharmaceutical Services has disclosed FCF Margin across 18 years of filings, most recently posting 7.55% for Q1 2026.

• FCF Margin for Q1 2026 came in at 7.55%, down 77.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 14.73% (down 550.0% YoY), and the FY2025 annual result was 15.25%, down 550.0% from the prior year.
• FCF Margin came in at 7.55% for Q1 2026 at West Pharmaceutical Services, down from 21.74% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 54.65% in Q4 2022 to a low of 6.75% in Q3 2024.
• The 5-year median for FCF Margin is 13.87% (2022), against an average of 17.8%.
• Across the five-year window, FCF Margin slumped 3684 bps in 2023 and surged 3683 bps in 2024, its largest moves.
• West Pharmaceutical Services' FCF Margin stood at 54.65% in 2022, then slumped by 67 bps to 17.81% in 2023, then surged by 207 bps to 54.65% in 2024, then tumbled by 60 bps to 21.74% in 2025, then plunged by 65 bps to 7.55% in 2026.
• The last three FCF Margin figures came in at 7.55% (Q1 2026), 21.74% (Q4 2025), and 16.64% (Q3 2025), per Business Quant data.